Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 1
1954 1
1963 1
1969 2
1970 1
1975 2
1978 4
1979 2
1980 1
1981 1
1982 1
1984 1
1986 1
1987 1
1988 2
1990 1
1991 1
1992 1
1993 1
1995 2
2001 4
2002 2
2003 10
2004 6
2005 3
2006 6
2007 4
2008 6
2009 16
2010 9
2011 11
2012 15
2013 18
2014 16
2015 23
2016 22
2017 19
2018 15
2019 30
2020 28
2021 40
2022 34
2023 36
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

367 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean lip and neoplasms (9,284 results)?
The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, Dupont N, Primard C, Proikas-Cezanne T, Reggiori F. Filali-Mouncef Y, et al. Autophagy. 2022 Jan;18(1):50-72. doi: 10.1080/15548627.2021.1895658. Epub 2021 Apr 2. Autophagy. 2022. PMID: 33794741 Free PMC article. Review.
Particular attention is paid to the role of macroautophagy and macrolipophagy in relation to the parenchymal and non-parenchymal cells of the liver in NASH, as this disease has been associated with inappropriate lipophagy in various cell types of the liver.Abbreviations: ACAT: ac …
Particular attention is paid to the role of macroautophagy and macrolipophagy in relation to the parenchymal and non-parenchymal cells of th …
LEP and LEPR polymorphisms in non-Hodgkin lymphoma risk: a systematic review and pooled analysis.
Lin HY, Shi H, Li CY, Chen QC, Huang TB, Liu PC, Lou LM. Lin HY, et al. J BUON. 2015 Jan-Feb;20(1):261-8. J BUON. 2015. PMID: 25778326 Free article. Review.
Odds ratios (ORs) with 95% confidence intervals (CIs) for LEP and LEPR polymorphisms and NHL were calculated with fixed-effects and random-effects models. ...Significant decrease of NHL risk was found in LEP A19G polymorphism, while no links were detected with the L …
Odds ratios (ORs) with 95% confidence intervals (CIs) for LEP and LEPR polymorphisms and NHL were calculated with fixed-effects and r …
LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K, Gillberg L, Mikkelsen SU, Ørskov AD, Schöllkopf C, Mortensen BK, Porse B, Hansen JW, Grønbæk K. Kaastrup K, et al. Clin Epigenetics. 2023 May 26;15(1):91. doi: 10.1186/s13148-023-01505-w. Clin Epigenetics. 2023. PMID: 37237325 Free PMC article.
We investigated whether LEP promoter methylation is an early event in the development of myeloid neoplasms and whether it is associated with clinical outcome. ...CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in …
We investigated whether LEP promoter methylation is an early event in the development of myeloid neoplasms and whether it is a …
Liposomal paclitaxel formulations.
Koudelka S, Turánek J. Koudelka S, et al. J Control Release. 2012 Nov 10;163(3):322-34. doi: 10.1016/j.jconrel.2012.09.006. Epub 2012 Sep 15. J Control Release. 2012. PMID: 22989535 Review.
Liposomal PTX formulations are in various stages of clinical trials. LEP-ETU (NeoPharm) and EndoTAG-1 (Medigene) have reached the phase II of the clinical trials; Lipusu (Luye Pharma Group) has already been commercialized. ...
Liposomal PTX formulations are in various stages of clinical trials. LEP-ETU (NeoPharm) and EndoTAG-1 (Medigene) have reached the pha …
LEP (-2548G>A LEP) and LEPR (223Gln>Arg, 109Lys>Arg) polymorphisms as breast cancer risk factors in the Polish female population.
Hołysz H, Paszel-Jaworska A, Romaniuk-Drapała A, Grodecka-Gazdecka S, Rubiś B. Hołysz H, et al. Mol Biol Rep. 2021 Apr;48(4):3237-3244. doi: 10.1007/s11033-021-06328-7. Epub 2021 Apr 17. Mol Biol Rep. 2021. PMID: 33864589 Free PMC article.
Therefore, new prognostic or diagnostic markers are required that would facilitate the assessment of patients or provide more efficient therapy, respectively. In these studies, we analyzed the contribution of LEP (2548G>A) and LEPR (109 Lys>Arg and 223Gln>Arg) gen …
Therefore, new prognostic or diagnostic markers are required that would facilitate the assessment of patients or provide more efficient ther …
Leptin and Beyond: Actors in Cancer.
Barone I, Giordano C. Barone I, et al. Biomolecules. 2021 Dec 6;11(12):1836. doi: 10.3390/biom11121836. Biomolecules. 2021. PMID: 34944480 Free PMC article.
Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients.
Zhang ZJ, Huang YP, Liu ZT, Wang YX, Zhou H, Hou KX, Tang JW, Xiong L, Wen Y, Huang SF. Zhang ZJ, et al. Front Immunol. 2023 Feb 2;14:1028404. doi: 10.3389/fimmu.2023.1028404. eCollection 2023. Front Immunol. 2023. PMID: 36817485 Free PMC article.
Immunohistochemical analysis showed that 6 gene (NLRX1, AKT1, CSRP1, LEP, MUC4 and SEMA4B) of 10 genes were abnormal expressions between cancer and paracancer tissue. ...
Immunohistochemical analysis showed that 6 gene (NLRX1, AKT1, CSRP1, LEP, MUC4 and SEMA4B) of 10 genes were abnormal expressions betw …
Evaluation of CYP17A1 and LEP Gene Polymorphisms in Breast Cancer.
Karakus N, Kara N, Ulusoy AN, Ozaslan C, Tural S, Okan I. Karakus N, et al. Oncol Res Treat. 2015;38(9):418-22. doi: 10.1159/000438940. Epub 2015 Aug 18. Oncol Res Treat. 2015. PMID: 26407154
The CYP17A1 and LEP gene polymorphisms were determined using polymerase chain reaction-based restriction fragment length polymorphism analysis. ...CONCLUSION: Our study suggests no strong association between the CYP17A1 T27C and LEP -2548G>A polymorphisms and the …
The CYP17A1 and LEP gene polymorphisms were determined using polymerase chain reaction-based restriction fragment length polymorphism …
Association of PON1, LEP and LEPR Polymorphisms with Susceptibility to Breast Cancer: A Meta-Analysis.
Sayad S, Dastgheib SA, Farbod M, Asadian F, Karimi-Zarchi M, Salari S, Shaker SH, Sadeghizadeh-Yazdi J, Neamatzadeh H. Sayad S, et al. Asian Pac J Cancer Prev. 2021 Aug 1;22(8):2323-2334. doi: 10.31557/APJCP.2021.22.8.2323. Asian Pac J Cancer Prev. 2021. PMID: 34452542 Free PMC article.
In this meta-analysis, the associations of polymorphisms within paraoxonase 1 (PON1), leptin (LEP) and leptin receptor (LEPR) genes with susceptibility to breast cancer were comprehensively evaluated. ...However, LEP rs7799039 and LEPR rs1137101 polymorphisms were n …
In this meta-analysis, the associations of polymorphisms within paraoxonase 1 (PON1), leptin (LEP) and leptin receptor (LEPR) genes w …
LTA, LEP, and TNF-a Gene Polymorphisms are Associated with Susceptibility and Overall Survival of Diffuse Large B-Cell lymphoma in an Arab Population: A Case-Control Study.
Al-Khatib SM, Abdo N, Al-Eitan LN, Al-Mistarehi AW, Zahran DJ, Kewan TZ. Al-Khatib SM, et al. Asian Pac J Cancer Prev. 2020 Sep 1;21(9):2783-2791. doi: 10.31557/APJCP.2020.21.9.2783. Asian Pac J Cancer Prev. 2020. PMID: 32986381 Free PMC article.
OBJECTIVE: In this study, we aimed to explore the relationship between five selected proinflammatory and immune-mediated genes (TNF rs1800629G>A, rs361525G>A, rs1799964T>C, LTA rs1800683G>A, rs909253A>G, TNFAIP8 rs1042541C>T, LEPR rs1327118G>C, and LEP …
OBJECTIVE: In this study, we aimed to explore the relationship between five selected proinflammatory and immune-mediated genes (TNF rs180062 …
367 results